secwatch.observer — SEC 8-K summary
======================================

Issuer:     Outlook Therapeutics, Inc. (OTLK)
CIK:        0001649989
Form:       8-K
Filed at:   2026-03-05T23:59:59+00:00
Accession:  0001104659-26-024189
Event type: regulatory
Sentiment:  neutral
Materiality: 0.55
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Outlook Therapeutics updates on Type A meeting with FDA for ONS-5010; no definitive resolution
--------------------------------------------------------------------------------

- Type A meeting held with FDA to discuss December 30, 2025 Complete Response Letter for ONS-5010 BLA.
- FDA had requested confirmatory evidence of effectiveness; no safety concerns identified by FDA.
- Company expects continued discussions to clarify agency views on confirmatory evidence.
- ONS-5010 met primary endpoints in Phase 3 NORSE TWO trial; NORSE EIGHT provided confirmatory efficacy/safety data.
- If approved, ONS-5010 would be first FDA-approved ophthalmic bevacizumab with US manufacturing supply chain.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1649989/000110465926024189/0001104659-26-024189-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1649989/000110465926024189/tm268164d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-024189

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer